What are you waiting for?

EN
  • Arabic - عربي
  • Chinese (traditional) - 中國傳統
  • Chinese (simplified) - 中国简化
  • English
  • Khmer - ភាសាខ្មែរ
  • Nepali - नेपाली
  • Pashto - پښتو
  • Persian - فارسى
  • Spanish - español
  • Swahili - Kiswahili
  • Vietnamese - tiếng việt
EN
  • Arabic - عربي
  • Chinese (traditional) - 中國傳統
  • Chinese (simplified) - 中国简化
  • English
  • Khmer - ភាសាខ្មែរ
  • Nepali - नेपाली
  • Pashto - پښتو
  • Persian - فارسى
  • Spanish - español
  • Swahili - Kiswahili
  • Vietnamese - tiếng việt
What are you waiting for?

FACT

The Pfizer COVID-19 vaccine was the first mRNA vaccine approved for use in Australia.

FACT

The Pfizer COVID-19 vaccine was the first mRNA vaccine approved for use in Australia.

The Pfizer COVID-19 vaccine is a messenger RNA (mRNA) vaccine that is approved for use in Australia for people aged 12 years and over. Two doses of the Pfizer vaccine are required for maximum protection against COVID-19, given between three and six weeks apart.1

The Pfizer COVID-19 vaccine is a messenger RNA (mRNA) vaccine. This type of vaccine uses a genetic code called RNA to make cells in the body produce the coronavirus’ specific spike protein. The immune system cells then recognise the spike protein as a threat and begin building an immune response against it.1

The Therapeutic Goods Administration (TGA) provisionally approved the Pfizer COVID-19 vaccine for use in Australia on 25 January 2021 (for 16 years and over) and then on 22 July 2021 (for 12 years and over).1, 2

As of 4 October 2021, 229.36 million doses of the Pfizer COVID-19 vaccine have been administered in the United States.3

Based on evidence from clinical trials that commenced back in April 2020, the Pfizer vaccine was 95% effective at preventing COVID-19 infection in people 16 years and older who received two doses and had no evidence of being previously infected.6, 7

Clinical trials also showed it was highly effective at preventing COVID-19 infection in adolescents 12 to 15 years old, and the immune response in people within this age group was at least as strong as the immune response in people 16 to 25 years old.7

Evidence shows mRNA COVID-19 vaccines, including Pfizer, offer similar protection in real-world conditions as they have in clinical trial settings and reduce the risk of COVID-19, including severe illness by 90% or more, among people who are fully vaccinated.7

Very rare and generally mild cases of myocarditis and pericarditis have been observed following vaccination with the Pfizer COVID-19 vaccine. Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining around the heart. There are many potential causes of myocarditis and pericarditis, including as a complication in people who are infected with COVID-19 or some other viruses.4, 5

The benefits of protection against COVID-19 far outweigh the risks from rare and generally mild side effects. Effects on the heart from COVID-19 infection are much more common and usually more severe than with rare effects from vaccination. The Australian Technical Advisory Group on Immunisation (ATAGI) reaffirms that the benefits of the Pfizer COVID-19 vaccine outweigh these rare risks.4, 5

 

 

 

More information

Related facts

Haven’t found what you are looking for?
Need more information about COVID-19?